30 Technology

30 Technology is excited to announce that on October 16, 2024, the first patient was enrolled into the NOPA study.

30 Technology is pleased to announce the successful completion of the interim analysis for Stage 1 of the Phase 2 trial evaluating RESP301 in the treatment of tuberculosis (RESP30X-EBA).

30 Technology is thrilled to announce approval for our Phase 1/2a trial designed to evaluate the safety, tolerability, and efficacy of nebulised Nitric Oxide Formulations

30 Technology is excited to announce that we have successfully completed the final dosing for all participants enrolled in our Tuberculosis study based in South Africa.

We are delighted to announce the first meeting of 30 Technology’s newly formed Scientific Advisory Board (SAB) held in our offices in Central London.

We are delighted to announce that our latest clinical trial ‘RESP30X-EBA’ is active and recruiting at the TASK Clinical Research Centre, South Africa.

30 Technology has been actively engaged in expanding its clinical team to drive its lead respiratory assets through multiple ongoing early phase clinical trials.

30 Technology is delighted to report that this month we received full regulatory approval to start our Phase 2 trial in adults with newly diagnosed pulmonary tuberculosis (TB).

30 Technology is delighted to announce the opening of its new Innovation Centre in Scale Space – a part of Imperial College London’s White City campus located in the heart of West London.